After publishing results of the PARADIGM-HF trial (Prospective Comparison of ARNI—Angiotensin Receptor/Neprilysin Inhibitors—with ACEI—Angiotensin-Converting Enzyme Inhibitor—to Determine Impact on Global Mortality and Morbidity in Heart Failure) in the year 2014, clinical investigators accelerated their research (Fig. 1). The gene discussed is ACE; the disease is heart failure.